Nabriva Therapeutics Reports Incentive Grant Under Nasdaq Listing Rule 5635 (c) (4)
Enter Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
DUBLIN, Ireland, Oct 01, 2021 (GLOBE NEWSWIRE) – Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today hui granting a non-legal stock option to purchase a total of 100,000 common shares of Nabriva Therapeutics as an inducement to Christopher Naftzger, Nabriva’s new legal advisor. This grant was awarded under the Nasdaq incentive grant exception as a component of new hire employment compensation.
The stock option was granted effective September 30, 2021 with an exercise price of $ 1.19 per share, which corresponds to the closing price of the common shares of Nabriva Therapeutics at the date of grant. The stock option has a 10-year term and vest over four years, with 25% of the initial number of shares vesting on the annual anniversary of the grant date until they vest in full, subject to the employee’s continued service with the Company through the applicable vesting period. Appointment. The grant of stock options was approved by the Compensation Committee of Nabriva Therapeutics and was granted as an incentive for the acceptance of employment by the new employee in accordance with the rule of Nasdaq listing 5635 (c) (4). The stock option is subject to the terms and conditions of a stock option agreement covering the grant and the 2021 stock incentive plan of Nabriva Therapeutics.
About Nabriva Therapeutics plc Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics has received approval from the United States Food and Drug Administration for XENLETA® (lefamulin injection, lefamulin tablets), the first systemic antibiotic based on pleuromutilin for the treatment of community-acquired bacterial pneumonia (CAP). Nabriva Therapeutics is also developing CONTEPO ™ (fosfomycin) for injection, a first-class epoxy antibiotic with potential for complicated urinary tract infections (cUTI), including acute pyelonephritis. Nabriva has entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, NJ, USA to market, sell and distribute SIVEXTRO® (tedizolid phosphate) in the United States and certain of its territories.
For investorsKim Anderson Nabriva Therapeutics plc[email protected]
For the mediaAndrea GreifOgilvy[email protected] 914-772-3027
Source: Nabriva Therapeutics US, Inc.